SMTI Relative Valuation
SMTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SMTI is overvalued; if below, it's undervalued.
Historical Valuation
Sanara Medtech Inc (SMTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -10.47. The fair price of Sanara Medtech Inc (SMTI) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 21.51 USD , Sanara Medtech Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：21.51
Fair
Undervalued
18.79
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Sanara Medtech Inc. (SMTI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 3.19. The thresholds are as follows: Strongly Undervalued below -25.06, Undervalued between -25.06 and -10.93, Fairly Valued between 17.32 and -10.93, Overvalued between 17.32 and 31.44, and Strongly Overvalued above 31.44. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
10.39
EV/EBIT
Sanara Medtech Inc. (SMTI) has a current EV/EBIT of 10.39. The 5-year average EV/EBIT is -8.95. The thresholds are as follows: Strongly Undervalued below -158.69, Undervalued between -158.69 and -83.82, Fairly Valued between 65.91 and -83.82, Overvalued between 65.91 and 140.78, and Strongly Overvalued above 140.78. The current Forward EV/EBIT of 10.39 falls within the Historic Trend Line -Fairly Valued range.
1.63
PS
Sanara Medtech Inc. (SMTI) has a current PS of 1.63. The 5-year average PS is 4.62. The thresholds are as follows: Strongly Undervalued below -0.35, Undervalued between -0.35 and 2.14, Fairly Valued between 7.11 and 2.14, Overvalued between 7.11 and 9.59, and Strongly Overvalued above 9.59. The current Forward PS of 1.63 falls within the Undervalued range.
0.00
P/OCF
Sanara Medtech Inc. (SMTI) has a current P/OCF of 0.00. The 5-year average P/OCF is 36.99. The thresholds are as follows: Strongly Undervalued below -457.58, Undervalued between -457.58 and -210.29, Fairly Valued between 284.28 and -210.29, Overvalued between 284.28 and 531.56, and Strongly Overvalued above 531.56. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Sanara Medtech Inc. (SMTI) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Sanara Medtech Inc (SMTI) has a current Price-to-Book (P/B) ratio of 30.60. Compared to its 3-year average P/B ratio of 9.25 , the current P/B ratio is approximately 230.97% higher. Relative to its 5-year average P/B ratio of 10.19, the current P/B ratio is about 200.28% higher. Sanara Medtech Inc (SMTI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.06%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -1.52% , the current FCF yield is about -100.00% lower.
31.66
P/B
Median3y
9.25
Median5y
10.19
-0.45
FCF Yield
Median3y
-1.06
Median5y
-1.52
Competitors Valuation Multiple
The average P/S ratio for SMTI's competitors is 6.32, providing a benchmark for relative valuation. Sanara Medtech Inc Corp (SMTI) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 21.51%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SMTI decreased by 34.34% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.86 to -30.82.
The secondary factor is the Revenue Growth, contributed 21.51%to the performance.
Overall, the performance of SMTI in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Sanara Medtech Inc (SMTI) currently overvalued or undervalued?
What is Sanara Medtech Inc (SMTI) fair value?
How does SMTI's valuation metrics compare to the industry average?
What is the current P/B ratio for Sanara Medtech Inc (SMTI) as of Dec 05 2025?
What is the current FCF Yield for Sanara Medtech Inc (SMTI) as of Dec 05 2025?
What is the current Forward P/E ratio for Sanara Medtech Inc (SMTI) as of Dec 05 2025?